• Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
Wednesday, May 25, 2022
No Result
View All Result
SUBSCRIBE
The Outlooker
27 °c
Delhi
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
No Result
View All Result
The Outlooker
No Result
View All Result
  • National
  • Politics
  • Opinion
  • Business
  • Science
  • World
  • Health
Home Business

Divi’s Laboratories rating – Reduce: Growth momentum was maintained

by The Outlooker Web Desk
June 5, 2021
in Business
0
Divi’s Laboratories rating – Reduce: Growth momentum was maintained
1.8k
SHARES
12.9k
VIEWS
Share on FacebookShare on Twitter

At 38X FY2023e P/E, valuations fully capture the superior growth in APIs, while ignoring the risks to the synthesis segment over the long-term. REDUCE

Divi’s continued its strong growth momentum in Q4FY21 with revenues/Ebitda exceeding our estimates by 6%/2%. Generics and synthesis business recorded 21%/22% y-o-y growth with gross margin expansion driving profitability. We believe market share gains across existing API portfolio and introduction of new products through capacity additions will help drive 17% EPS CAGR over FY2021-24e. At 38X FY2023e P/E, valuations fully capture the superior growth in APIs, while ignoring the risks to the synthesis segment over the long-term. REDUCE

In-line quarter; strong revenue growth to cap off an impressive FY2021
Divi’s posted 29% y-o-y revenue growth in Q4FY21. Generics segment grew 22% y-o-y led by continued traction in key molecules while custom synthesis witnessed 22% y-o-y growth with commercial shipments of molnupiravir aiding growth. Cartenoids segments recorded sharp 68% y-o-y growth. Gross margins declined 150bps q-o-q to 67.5%. Despite a sharp jump in other expenses sequentially, Ebitda was 2% ahead of our estimates with Ebitda margins remaining healthy at 40.1%. Divi’s incurred a capex of `91 bn and generated FCF of Rs 10 bn in FY2021.

Long runway for growth in API business; molnupiravir to support synthesis growth in near term
With continued capacity addition, we believe Divi’s is well positioned to gain share from competitors in existing products. With capacity related bottlenecks now addressed, Divi’s has also identified a new set of products with patent expiries from 2023-25, where it is aiming for market leadership. We expect strong market share gains and introduction of new APIs to drive robust 16% sales CAGR in generics segment over FY2021-23e. In the synthesis segment, we expect robust near term growth.

Increase FY2022-23E estimates by 5%
We increase our FY2022-23e EPS estimates by 5% each to bake in higher molnupiravir sales through supplies to Indian VL partners. However, at 38X FY2023e P/E and 27X FY2023e Ebitda, the stock fully captures strong medium term growth. Revise FV to `3,750 (from `3,300 earlier) based on 35X FY2023e EPS.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

The Outlooker is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

The Outlooker Web Desk

The Outlooker Web Desk

Next Post
Coronavirus: State With Small Population, But Not Enough Vaccines: Sikkim High Court

Coronavirus: State With Small Population, But Not Enough Vaccines: Sikkim High Court

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Delhi Positivity Rate Falls To 13% From 16.3%, Cases Down 19% To 9,197
National

Coronavirus India LIVE Updates, Coronavirus Cases Today, COVID 19 Cases In India, Omicron Covid Cases, India Covid Cases May 25

May 25, 2022
Global Markets: Stocks slump on growth concerns, bond yields slip
Business

Global Markets: Stocks slump on growth concerns, bond yields slip

May 24, 2022
Tamil Nadu BJP Leader Balachandran Hacked To Death In Chennai: Police
National

Tamil Nadu BJP Leader Balachandran Hacked To Death In Chennai: Police

May 24, 2022
Coal India To Open Big, New Mine This Year To Fight Power Crisis
National

Coal India To Open Big, New Mine This Year To Fight Power Crisis

May 24, 2022

Connect with us

No Result
View All Result

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020

Category

  • Artistic
  • Business
  • Crypto
  • Design
  • Entertainment
  • Fashion
  • featured
  • Food
  • Gaming
  • Health
  • Human
  • Lifestyle
  • Movie
  • Music
  • National
  • Opinion
  • Politics
  • Science
  • Spaces
  • Sports
  • Tech
  • Travel
  • Uncategorized
  • World

Recent Posts

  • Coronavirus India LIVE Updates, Coronavirus Cases Today, COVID 19 Cases In India, Omicron Covid Cases, India Covid Cases May 25
  • Global Markets: Stocks slump on growth concerns, bond yields slip
  • Tamil Nadu BJP Leader Balachandran Hacked To Death In Chennai: Police

About Us

The Outlooker

The Outlooker is your source of authentic, hand-picked news, stories, analysis from India & the World.

  • Terms Of Service
  • Privacy Policy
  • About us
  • Submit your story
  • Contact

© 2019-2021 The Outlooker. All rights reserved.

No Result
View All Result
  • Home
  • Politics
  • World
  • Business
  • Science
  • National
  • Entertainment
  • Gaming
  • Movie
  • Music
  • Sports
  • Fashion
  • Lifestyle
  • Travel
  • Tech
  • Health
  • Food

© 2019-2021 The Outlooker. All rights reserved.